BioSpace News Archive

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber , PhD, will deliver a corporate presentation at the BIO CEO & Investor Digital Conference taking place February 16-18, 2021.

Almirall announced today that the New England Journal of Medicine (NEJM) has published the results from the pivotal Phase III trials of Klisyri® (tirbanibulin) ointment for actinic keratosis.

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will present a corporate overview at the LifeSci Partners Precision Oncology Day

EnginZyme seeks to transform the $5 trillion chemical industry through the use of its enzyme-based platform, which combines the breadth and power of nature with the efficiencies of state-of-the-art chemical processing techniques

Rentschler Biopharma will establish their ATMP development and manufacturing capabilities at the Cell and Gene Therapy Catapult facility in Stevenage

Solid full year 2020 results in a COVID-19 environment, with Group sales growth of 3.0%1 and Core Operating margin at 32.0%

Immunovia is pleased to invite investors, analysts and media to a teleconference with web presentation on Wednesday, February 17, 2021 at 16:30 pm CET.

Cue Health Inc. announced the results of an independent clinical validation study conducted by Mayo Clinic Laboratories evaluating the accuracy of Cue’s COVID-19 Test in the point-of-care setting against the centralized lab PCR testing model.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that the Company will release fourth quarter and fiscal year 2020 operating results after the close of the market on Monday, March 1, 2021.

Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, will participate in the virtual SVB Leerink Global Healthcare Conference on February 24, 2021.